Details of the Drug Reposition
General Information of This Drug (ID: DMDNBJ1)
| Drug Name | ||||||
|---|---|---|---|---|---|---|
| Synonyms |
Retinal pigment epithelium program, ACT; MA09-hRPE cells (ocular disease); Embryonic stem-derived retinal pigmented epithelial cell therapy (ocular disease), CHA Bio Diostech; Stem cell-derived therapy (macular degeneration), Advanced Cell Technology; Retinal pigment epithelium program, (ocular disease), CHA Bio & Diostech; Stem cell-derived therapy (ocular disease), CHA Bio & Diostech; MA09-hRPE cells (ocular disease), Advanced Cell Technology/CHA Bio & Diostech; ES-derived RPE cell therapy (retinitis pigmentosa/Stargardt's disease/AMD), ACTC; Embryonic stem-derived retinal pigmented epithelial cell therapy (retinitis pigmentosa/Stargardt's disease/age related macular degeneration), Advanced Cell Technology; HESC-derived RPE cells (retinitis pigmentosa/Stargardt's disease/age related macular degeneration/ocular disease), Advanced Cell Technology
|
|||||
Information on Drug Reposition of This Drug
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
2 Phase 1/2 Indication(s)
|
|
||||||||||||||||||||||||||||||
References